Cargando…

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma

Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Topcu, Atakan, Ozturk, Akin, Yurtsever, Ismail, Besiroglu, Mehmet, Yasin, Ayse Irem, Turk, Haci Mehmet, Seker, Mesut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589317/ https://www.ncbi.nlm.nih.gov/pubmed/35575465 http://dx.doi.org/10.17305/bjbms.2022.7147

Ejemplares similares

Anxiety levels of breast cancer patients in Turkey during the COVID-19 pandemic
por: Yasin, Ayse Irem, et al.
Publicado: (2021)

Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer
por: Bilgin, Sabriye Sennur, et al.
Publicado: (2021)

Diagnostic Performance of Apparent Diffusion Coefficient Values for The Differentiation of Intrahepatic Cholangiocarcinoma from Gastrointestinal Adenocarcinoma Liver Metastases
por: Yilmaz, Temel Fatih, et al.
Publicado: (2021)

Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study
por: Simsek, Melih, et al.
Publicado: (2022)

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2014)

Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?
por: Kus, Tulay, et al.
Publicado: (2015)

Prognostic impact of initial maximum standardized uptake value of (18)F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib
por: Kus, Tulay, et al.
Publicado: (2015)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study
por: Aydin, Sabin Goktas, et al.
Publicado: (2023)

Incidental detection of prostate-specific antigen-negative metastatic prostate cancer initially presented with solitary pulmonary nodule on fluorodeoxyglucose positron emission tomography/computed tomography
por: Erdogan, Ezgi Basak, et al.
Publicado: (2015)

Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma
por: Kurishima, Koichi, et al.
Publicado: (2014)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
por: Gonçalves, Ivone, et al.
Publicado: (2013)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines
por: Wang, Hui-Li, et al.
Publicado: (2019)

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma
por: Jiang, Shiyao, et al.
Publicado: (2022)

Dramatic Improvement of Severe Cicatricial Ectropion after Discontinuing Long-Term Erlotinib Therapy in a Patient with Lung Cancer
por: Mangan, Mehmet Serhat
Publicado: (2022)

Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report
por: Jovanovic, Dragana, et al.
Publicado: (2017)

Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib
por: Shahriari, Saeedeh, et al.
Publicado: (2022)

MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Synchronous Hepatocellular Carcinoma and Cholangiocellular Carcinoma on (18)F-FDG PET/CT
por: Erdoğan, Ezgi Başak, et al.
Publicado: (2018)

Long Term Survivor with Erlotinib in Metastatic Lung Cancer-Squamous Cell Carcinoma Subtype
por: VATU, BOGDAN IONEL, et al.
Publicado: (2020)

Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
por: Yasin, Ayse Irem, et al.
Publicado: (2022)

Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung
por: HUANG, CHU-YUN, et al.
Publicado: (2014)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma
por: Bell, Ann T., et al.
Publicado: (2017)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
por: Nakagawa, Kazuhiko, et al.
Publicado: (2022)

The Effect of Single High-Dose Preoperative Intravenous Tranexamic Acid Administration to Reduce Blood Loss in Patients with Primary Total Knee Replacement
por: Talmaç, Mehmet Ali, et al.
Publicado: (2019)

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
por: Wainberg, Z A, et al.
Publicado: (2011)

Evaluation of Toxic Effects of Chemotherapy in Lung Malignancies on Cerebral White Matter Using Diffusion Tensor Imaging
por: Aydin, Sinem, et al.
Publicado: (2022)

Treatment of tissue necrosis with hyperbaric oxygen therapy in a patient with pseudomonas endophthalmitis and orbital cellulitis: a case report
por: Uyanik, Ismail, et al.
Publicado: (2023)

Comparison of two surgical techniques for Lisfranc injuries; closed reduction and fixation versus primary partial arthrodesis
por: Sönmez, Mehmet Mesut, et al.
Publicado: (2023)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_197lguvaqbf7dkbd0hciu5op4g